One-minute decision guide
The simple evidence-based answer
Do not buy IV NAD as a proven anti-aging, energy or addiction treatment. Human outcome evidence is absent, and oral precursor studies cannot validate an infusion. If a clinician proposes it, ask what diagnosis is being treated, whether an approved alternative exists, the exact compounded product and pharmacy, sterility controls, dose, infusion rate, expected measurable outcome and stop rules. Chest pressure, marked nausea, shaking and rapid heart rate are reported during infusions; contamination and endotoxin reactions can require medical treatment.See reference 1,See reference 2,See reference 3
The 10 rules to remember
- Use IV NAD therapy only for a clearly defined problemSee reference 1
- Start with the lowest-burden evidence-based optionSee reference 2
- Record a baseline before changing anythingSee reference 3
- Do not confuse a biological mechanism with a proven health outcomeSee reference 4
- Do not let IV NAD therapy replace established careSee reference 5
- Use qualified clinical oversight when the intervention is medicalSee reference 6
- Stop when harms, abnormal symptoms or a worse trend appearSee reference 7
- Judge benefit with measurements that matter to the original goalSee reference 8
- Reassess cost, burden and uncertainty after the planned trialSee reference 9
- Avoid protocols based only on testimonials, influencers or clinic marketingSee reference 10
First principles: what this can actually change
NAD is essential inside cells, but an IV molecule reaching blood does not guarantee useful uptake into target tissues.See reference 1,See reference 2
Raising a metabolite or precursor is target engagement, not proof of better energy, cognition, recovery or lifespan.See reference 3,See reference 4
Any sterile infusion adds vascular-access, contamination and compounding risks that oral products do not.See reference 5,See reference 6
A practical decision protocol
| Stage | What to do | Why it matters |
|---|---|---|
| 1. Define indication | Ask for the diagnosis and patient-important endpoint | Wellness language is not a clinical indicationSee reference 1,See reference 2 |
| 2. Verify product | Identify pharmacy, ingredient grade, sterility and traceability | Compounding quality can determine harmSee reference 3,See reference 4 |
| 3. Set stop rules | Document rate-related and allergic or endotoxin symptoms | Infusion reactions are commonSee reference 5,See reference 6 |
| 4. Compare value | Evaluate outcome against cost and safer alternatives | Biological plausibility alone is low valueSee reference 7,See reference 8 |
Timing, dose and frequency
| Decision | Practical answer |
|---|---|
| Before infusion | Review pregnancy, kidney or liver disease, medicines, allergies and prior reactions.See reference 1,See reference 2 |
| During infusion | Use trained monitoring and report chest pressure, cramping, nausea or shaking immediately.See reference 3,See reference 4 |
| Course length | No evidence-based wellness series or maintenance frequency exists.See reference 5,See reference 6 |
| After a reaction | Do not simply slow and repeat before the product and cause are investigated.See reference 7,See reference 8 |
What to measure
| Signal | How | Interpretation |
|---|---|---|
| Patient-important goal | Use a validated fatigue, function or disease measure | A vague energy feeling is highly expectation-sensitiveSee reference 1,See reference 2 |
| Vital signs and symptoms | Monitor during and after infusion | Rate-related or contamination reactions can be acuteSee reference 3,See reference 4 |
| Product provenance | Record lot, pharmacy and dose | Traceability is essential after an adverse eventSee reference 5,See reference 6 |
| Total cost | Include travel, time and repeated packages | Opportunity cost can exceed any unproven benefitSee reference 7,See reference 8 |
What the evidence actually shows
A 2026 PRISMA review found no eligible clinical outcomes trial of IV or intramuscular NAD itself for anti-aging or wellness.See reference 1,See reference 2
A small 2026 retrospective commercial pilot reported more gastrointestinal symptoms, heart-rate increase and chest pressure with IV NAD than IV NR.See reference 3,See reference 4
FDA has warned about food-grade ingredients used in sterile NAD compounding and reports of severe chills, shaking, vomiting and fatigue consistent with endotoxin exposure.See reference 5,See reference 6
Evidence strength by claim
| Claim | Confidence | Important boundary |
|---|---|---|
| Changes circulating NAD metabolites | Moderate | Biochemical change is not clinical benefitSee reference 1,See reference 2 |
| Improves energy or fatigue | Very low | No robust controlled IV NAD outcomesSee reference 3,See reference 4 |
| Treats addiction or cognitive decline | Very low | Condition-specific efficacy not establishedSee reference 5,See reference 6 |
| Slows aging or extends life | Very low | No human outcome evidenceSee reference 7,See reference 8 |
Limits and common overclaims
NAD, NADH, NR and NMN are different interventions and cannot be treated as interchangeable.See reference 4,See reference 7
Commercial clinic data are vulnerable to selection, placebo and reporting bias.See reference 5,See reference 8
Long-term safety of repeated infusions in healthy consumers is unknown.See reference 6,See reference 9
A four-step implementation plan
- 1. Ask for the diagnosis and patient-important endpointSee reference 1
- 2. Identify pharmacy, ingredient grade, sterility and traceabilitySee reference 2
- 3. Document rate-related and allergic or endotoxin symptomsSee reference 3
- 4. Evaluate outcome against cost and safer alternativesSee reference 4
Troubleshooting
| Problem | Likely issue | Better next step |
|---|---|---|
| Chest pressure or cramping | Infusion intolerance or rate effect | Stop and obtain clinical assessmentSee reference 1,See reference 2 |
| Shaking or feverish reaction | Possible endotoxin or contamination | Treat medically and report the productSee reference 3,See reference 4 |
| No durable change | The mechanism did not translate clinically | Do not automatically buy a larger packageSee reference 5,See reference 6 |
| Clinic cannot identify pharmacy | Traceability failure | Do not proceedSee reference 7,See reference 8 |
Safety and when to get medical help
IV therapy can cause infection, vein injury, fluid problems, allergic reactions and contaminated-product illness. FDA has received reports of severe reactions after injectable NAD products. Seek urgent care for chest pain, breathing difficulty, fainting, high fever, severe shaking, confusion or facial swelling. Report suspected product reactions through the appropriate regulator.See reference 1,See reference 5,See reference 9
Who is most likely to benefit
Research participants in a regulated trial designed to answer a specific NAD question.See reference 2,See reference 6
Patients with a separately established medical indication only when a qualified team can justify the route and product.See reference 3,See reference 7
Healthy consumers seeking energy or longevity have no proven outcome benefit to balance the cost and infusion risk.See reference 4,See reference 8
Track five things
- Patient-important goalSee reference 1
- Vital signs and symptomsSee reference 3
- Product provenanceSee reference 5
- Total costSee reference 7
- Decision made after reviewing the resultSee reference 9
Frequently asked questions
Does IV work better than oral NAD precursors?
No comparative outcomes evidence establishes that it does.See reference 1
How many infusions?
No evidence-based anti-aging course or maintenance schedule exists.See reference 2
Why can it feel uncomfortable?
Rapid NAD infusions are reported to cause nausea, cramping, chest pressure and heart-rate changes.See reference 3
Is compounded NAD FDA approved?
A compounded preparation is not reviewed like an FDA-approved product for safety, effectiveness and manufacturing consistency.See reference 4
Does this extend lifespan?
No human trial has shown that IV NAD therapy extends lifespan. Any longevity claim must be separated from evidence for a specific symptom, diagnosis or surrogate marker.See reference 5
How quickly should it work?
Review pregnancy, kidney or liver disease, medicines, allergies and prior reactions.See reference 6
Can it replace standard treatment?
No. A complementary tool should not displace care already shown to reduce symptoms, complications or mortality.See reference 7
How do I know whether it helped?
Use a pre-defined outcome such as patient-important goal and compare it with a baseline over an appropriate time window.See reference 8
Connect this decision to your wider health picture
LongevityMate helps organize measurements, symptoms, habits and trends so one test, device or treatment stays in context instead of becoming the whole plan.
See how LongevityMate worksReferences
- 1. NAD Supplementation for Anti-Aging and Wellness
Ageing Research ReviewsSystematic review
- 2. Safety and Effectiveness of NAD in Clinical Conditions
American Journal of PhysiologySystematic review
- 3. Intravenous NAD and NR Tolerability Pilot
Frontiers in AgingObservational study
- 4. Human NAD Metabolome During IV Infusion
Frontiers in Aging NeuroscienceObservational study
- 5. Sterile Compounding and Injectable NAD
U.S. Food and Drug AdministrationOfficial guidance
- 6. Targeting Ageing With Rapamycin and Rapalogs
The Lancet Healthy LongevitySystematic review
- 7. Safe Use of Hyperbaric Oxygen Therapy Devices
U.S. Food and Drug AdministrationOfficial guidance
- 8. Understanding Unapproved Use of Approved Drugs
U.S. Food and Drug AdministrationOfficial guidance
- 9. Warning About Unapproved Human Cell and Tissue Products
U.S. Food and Drug AdministrationOfficial guidance
- 10. Bulk Drug Substances With Significant Safety Risks
U.S. Food and Drug AdministrationOfficial guidance
Editorial transparency
- Published by
- LongevityMate Editorial Team
- Published
- Updated
Medical disclaimer
This guide provides general health education. It does not diagnose a condition, prescribe treatment, replace individualized medical care, or guarantee a health or longevity outcome.